MIRA Pharmaceuticals (NASDAQ:MIRA) | WebDisclosure

Basculer en Français

8295	Companies
114810	Keywords
55260	Articles
62423	Press releases

Home
Companies
MIRA Pharmaceuticals

BRIEF

published on 11/20/2024 at 13:49, 20 hours 10 minutes ago

MIRA Pharmaceuticals lance des essais cliniques sur le kétamir-2

Essai Clinique Ketamir-2 MIRA Pharmaceutique Technologie PainCart Traitement Non Addictif
BRIEF

published on 11/20/2024 at 13:49, 20 hours 10 minutes ago

MIRA Pharmaceuticals Initiates Ketamir-2 Clinical Trials

Clinical Trial MIRA Pharmaceuticals Ketamir-2 PainCart Technology Non-addictive Treatment
PRESS RELEASE

published on 11/20/2024 at 13:44, 20 hours 15 minutes ago

MIRA Reveals Innovative Phase I/IIa Protocol Design and Selection of Clinical Trial Site
MIRA Pharmaceuticals progresses towards clinical-stage status with Phase I/IIa trial announcement on Ketamir-2, a novel oral ketamine analog, for pain management. CHDR's PainCart technology leveraged

Pain Management MIRA Pharmaceuticals Ketamir-2 Clinical-stage Company Phase I/IIa Trial
BRIEF

published on 10/28/2024 at 12:35, 23 days 21 hours ago

MIRA Pharmaceuticals révèle des résultats précliniques prometteurs pour le kétamir-2

Résultats Précliniques Ketamir-2 Douleur Neuropathique MIRA Pharmaceutique Désignation De La FDA
BRIEF

published on 10/28/2024 at 12:35, 23 days 21 hours ago

MIRA Pharmaceuticals Reveals Promising Preclinical Results for Ketamir-2

Preclinical Results MIRA Pharmaceuticals Ketamir-2 Neuropathic Pain FDA Designation
PRESS RELEASE

published on 10/28/2024 at 12:30, 23 days 21 hours ago

MIRA Pharmaceuticals' Ketamir-2 Shows 60% Greater Efficacy Than FDA-Approved Gabapentin in Reversing Chemotherapy-Induced Neuropathic Pain
MIRA Pharmaceuticals announces promising preclinical results for Ketamir-2, a potential breakthrough therapy surpassing current treatments. Study shows 60% greater efficacy than gabapentin in reducing chemotherapy-induced pain, to be presented at Pain Therapeutics Summit

Pain Management Preclinical Results MIRA Pharmaceuticals Ketamir-2 Breakthrough Therapy
BRIEF

published on 10/21/2024 at 13:35, 30 days 20 hours ago

MIRA Pharmaceuticals présente le kétamir-2 comme une alternative prometteuse au traitement de la douleur

Étude Préclinique Ketamir-2 Douleur Neuropathique MIRA Pharmaceutique Gabapentine Et Prégabaline
BRIEF

published on 10/21/2024 at 13:35, 30 days 20 hours ago

MIRA Pharmaceuticals Introduces Ketamir-2 as a Promising Pain Relief Alternative

Preclinical Study MIRA Pharmaceuticals Ketamir-2 Neuropathic Pain Gabapentin And Pregabalin
PRESS RELEASE

published on 10/21/2024 at 13:30, 30 days 20 hours ago

MIRA Pharmaceuticals Announces Ketamir-2 Outperforms Current FDA-Approved Neuropathic Pain Treatments, Gabapentin and Pregabalin, in Preclinical Study
MIRA Pharmaceuticals, Inc. announces promising results for novel oral ketamine analog Ketamir-2 in providing superior pain relief compared to current treatments. Preparing for Phase 1 clinical trials and exploring potential in PTSD

Clinical Trials PTSD MIRA Pharmaceuticals Ketamir-2 Neuropathic Pain
BRIEF

published on 09/27/2024 at 13:35, 1 month 23 days ago

MIRA Pharmaceuticals Reveals New Data on Ketamir-2 at Annual Pain Therapeutics Summit

Preclinical Data MIRA Pharmaceuticals Ketamir-2 Neuropathic Pain Pain Therapeutics Summit

1 2 ... 4

Accesswire

Published on 11/21/2024 at 09:00, 59 minutes ago

ProScore Announces Domestic Content Solution for Inflation Reduction Act Requirements
Published on 11/21/2024 at 00:35, 9 hours 24 minutes ago

Vision Marine Technologies Establishes a Strategic Hub for Electric Boat Sales, Rentals, and Distribution, Marking a Milestone at Dania Pointe’s Grand Opening of Aileron Residences
Published on 11/21/2024 at 00:25, 9 hours 34 minutes ago

Biomind Labs Welcomes U.S. Policy Shift as a Historic Milestone for Psychedelic Therapies
Published on 11/21/2024 at 00:00, 9 hours 59 minutes ago

Swiss Mining Institute Conference Presentation
Published on 11/20/2024 at 23:00, 10 hours 59 minutes ago

Rektron Group Inc. Announces Appointment of a New Director and Provides Corporate Updates

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 09:41, 17 minutes ago

Original-Research: 2G Energy AG (von First Berlin Equity Research GmbH): Buy
Published on 11/21/2024 at 09:01, 57 minutes ago

Original-Research: Netfonds AG (von NuWays AG): Buy
Published on 11/21/2024 at 08:59, 59 minutes ago

Black Friday Savings: Kling AI Offers 50% Off and Free Feature Upgrades
Published on 11/21/2024 at 08:59, 59 minutes ago

Économies Black Friday : Kling AI propose 50 % de réduction et des mises à niveau gratuites des fonctionnalités
Published on 11/21/2024 at 08:15, 1 hour 44 minutes ago

EBIT increases to EUR 55.6 million. Equity (net asset value) increases by EUR 49.3 million to EUR 300.3 million, which corresponds to 70.14 euros per share. The equity ratio rises to 94.85%.

Les Echos

Published on 11/21/2024 at 06:58, 3 hours 1 minute ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 3 hours 1 minute ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 3 hours 1 minute ago

Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 13 hours 51 minutes ago

Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 14 hours 39 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting

View all LES ECHOS COMFI WIRE